Lead Product(s): Pretomanid
Therapeutic Area: Pulmonary/Respiratory Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: TB Alliance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 16, 2020
The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen.